Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
The ongoing ALIGN trial evaluates the efficacy and safety of atrasentan in a representative global IgAN population at risk for disease progression despite optimized RAS inhibitor therapy and includes an exploratory stratum evaluating atrasentan use in combination with an SGLT2i.
Authors
- Marianne Camargo (ORCID: https://orcid.org/0000-0003-2568-0105)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Adrian Liew (ORCID: https://orcid.org/0000-0002-0963-6270)
- Todd Gray
- Adeera Levin (ORCID: https://orcid.org/0000-0003-2438-8401)
- Jonathan Barratt (ORCID: https://orcid.org/0000-0002-9063-7229)
- Irene de Lourdes Noronha
- Richard Lafayette (ORCID: https://orcid.org/0000-0003-3906-7934)
- Alan G. Jardine (ORCID: https://orcid.org/0000-0001-5815-9370)
- Ronny Renfurm
- Donald E. Kohan (ORCID: https://orcid.org/0000-0002-3981-2941)
- Hong Zhang (ORCID: https://orcid.org/0000-0003-4037-7497)
- Hernán Trimarchi
- Fan Fan Hou
Institutions
- Novartis (Switzerland) (CH)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University of Leicester (GB)
- University of Groningen (NL)
- Peking University (CN)
- University of Utah (US)
- Mount Elizabeth Novena Hospital (SG)
- Nanfang Hospital (CN)
- Nova Research Company (United States) (US)
- The George Institute for Global Health (AU)
- Beneficência Portuguesa de São Paulo (BR)
- Novartis (United States) (US)
- Peking University First Hospital (CN)
- Hospital Británico de Buenos Aires (AR)
- Southern Medical University (CN)
- Stanford University (US)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1016/j.ekir.2024.10.004
- Citations
- 11
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 3.73
Funders
- Novartis